Biologically active polypeptides derived from a novel early...

Details Biologically active polypeptides derived from a novel early... Biologically active polypeptides derived from a novel early...

2011-08-09

2011-08-09

Parkin, Jeffrey (Department: 1648)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

25 or more amino acid residues in defined sequence

C530S326000, C530S329000

Reexamination Certificate

active

07994278

ABSTRACT:
The invention relates to therapeutic polypeptides isolated from beta-human chorionic gonadotropin (β-hCG) found in human early pregnancy urine, now synthetically produced and designated Maternin. The therapeutic polypeptides and their functional equivalents are useful in treating and/or preventing various medical conditions. Examples of therapeutic effects of the therapeutic polypeptides include anti-HIV, anti-cancer, anti-wasting, prohematopoietic (e.g., anemias, radiation-mediated bone marrow damage, and trauma-mediated blood loss), and anti-angiogenic effects. The invention also provides pharmaceutical compositions comprising the therapeutic polypeptides, as well as methods for using the therapeutic polypeptides, functional equivalents and/or pharmaceutical compositions in the treatment and/or prevention of such medical conditions.

REFERENCES:
patent: 4161519 (1979-07-01), Talwar
patent: 4201770 (1980-05-01), Stevens
patent: 4400316 (1983-08-01), Katsuragi et al.
patent: 4689222 (1987-08-01), McMichael
patent: 4691006 (1987-09-01), Stevens
patent: 4692332 (1987-09-01), McMichael
patent: 4713366 (1987-12-01), Stevens
patent: 4714680 (1987-12-01), Civin et al.
patent: 4762913 (1988-08-01), Stevens
patent: 4767842 (1988-08-01), Stevens
patent: 4780312 (1988-10-01), Talwar
patent: 4855285 (1989-08-01), Stevens
patent: 4880626 (1989-11-01), McMichael
patent: 4966753 (1990-10-01), McMichael
patent: 5004681 (1991-04-01), Boyse et al.
patent: 5061620 (1991-10-01), Tsukamoto et al.
patent: 5141867 (1992-08-01), Ivanoff et al.
patent: 5192553 (1993-03-01), Boyse et al.
patent: 5380668 (1995-01-01), Herron
patent: 5445968 (1995-08-01), Blithe et al.
patent: 5451527 (1995-09-01), Sarin et al.
patent: 5494899 (1996-02-01), Kincade et al.
patent: 5508261 (1996-04-01), Moyle et al.
patent: 5610136 (1997-03-01), McMichael
patent: 5614612 (1997-03-01), Haigwood et al.
patent: 5635599 (1997-06-01), Pastan et al.
patent: 5677275 (1997-10-01), Lunardi-Iskandar et al.
patent: 5700781 (1997-12-01), Harris
patent: 5811390 (1998-09-01), Bourinbaiar
patent: 5877148 (1999-03-01), Lunardi-Iskandar et al.
patent: 5877159 (1999-03-01), Powell et al.
patent: 5968513 (1999-10-01), Gallo et al.
patent: 5997871 (1999-12-01), Gallo et al.
patent: 6013857 (2000-01-01), Deboer et al.
patent: 6156952 (2000-12-01), Bryant et al.
patent: 6319504 (2001-11-01), Gallo et al.
patent: 6331610 (2001-12-01), Bourinbaiar
patent: 6583109 (2003-06-01), Gallo et al.
patent: 6620416 (2003-09-01), Gallo et al.
patent: 6699656 (2004-03-01), Gallo et al.
patent: 0 049 898 (1982-04-01), None
patent: 0 142 387 (1985-05-01), None
patent: 0 211 411 (1987-02-01), None
patent: 0323769 (1988-11-01), None
patent: 04300896 (1992-10-01), None
patent: WO 86/04241 (1986-07-01), None
patent: WO 87/03487 (1987-06-01), None
patent: WO 90/02759 (1990-03-01), None
patent: WO9108228 (1991-06-01), None
patent: WO 91/09872 (1991-07-01), None
patent: WO 91/16921 (1991-11-01), None
patent: WO 92/22654 (1992-12-01), None
patent: WO9222568 (1992-12-01), None
patent: WO 94/20859 (1994-09-01), None
patent: WO 94/24148 (1994-10-01), None
patent: WO 96/04008 (1996-02-01), None
patent: WO97/49373 (1997-12-01), None
patent: WO 97/49418 (1997-12-01), None
patent: WO9749373 (1997-12-01), None
patent: WO99/06438 (1999-02-01), None
patent: WO9906438 (1999-02-01), None
patent: WO9925849 (1999-05-01), None
Morgan, F. J., et al., 1975, The amino acid sequence of human chorionic gonadotropin: The alpha subunit and beta subunit, J. Biol. Chem. 250(13):5247-5258.
Gait, M. J., and J. Karn, 1995, Progress in anti-HIV structure-based drug design, TIBTECH 13:430-438.
Hirsch, M. S., et al., 1998, Antiretroviral drug resistance testing in adults with HIV infection: Implications for clinical management, JAMA 279(24):1984-1991.
Bodey, B., et al., 2000, Genetically engineered monoclonal antibodies for direct anti-neoplastic treatment and cancer cell specific delivery of chemotherapeutic agents, Curr. Pharm. Desgin 6:261-276.
Lesniak, M. S., et al., 2001, Drug delivery to tumors of the central nervous system, Curr. Neurol. Neurosci. Reports 1:210-216.
Alfthan et al. (1992) Cancer Res. 52: 4628-4633.
Bagshawe (1992) Acta Oncol. 31: 99-106.
Bidart, J-M et al., “Human Chorionic Gonadotropin Molecular Forms, Detection, and Clinical Implications.” TEM 4:285 (1993).
Birken, S. et al., “Structure of the Human Chorionic Gonadotropin .beta.-Subunit Fragment from Pregnancy Urine.” Endocrinology 123:572 (1988).
Bourinbaiar, A.S. et al., “Pregnancy hormones, estrogen and progesterone, prevent HIV-1 synthesis in monocytes but not in lymphocytes.” FEBS Letters 302:206 (1992).
Chen, W. et al., “Recombinant Carbohydrate Variant of Human Choriogonadotropin .beta.-Subunit (hCG.beta.) Descarboxyl Terminus (115-145).” Journal of Biological Chemistry 266:6246 (1991).
Cole, L.A., et al., “The Deactivation of hCG by Nicking and Dissociation” Journal of Clinical Endocrinology and Metabolism 76:704 (1993).
Cole Laurence A. et al., “The Heterogeneity of Human Chorionic Gonadotropin (hCG). III. The Occurrence and Biological and Immunological Activities of Nicked hCG.” Endocrinology 129:1559 (1991).
Curti, Critical Reviews in Oncology/Hematology, vol. 14, pp. 29-39, 1993.
Danforth, D.N., Jr., M.D., “How Subsequent Pregnancy Affects Outcome in Women with a Prior Breast Cancer.” Oncology 5:23 (1991).
Elford et al. (1993) AIDS 7: 1667-1671.
Freireich, E.J. et al., “Quantitative Comparison of Toxicity of Anticancer Agents in Mouse, Rat, Hamster, Dog, Monkey, and Man.” Cancer Chemotherapy Reports 50:219 (1966).
Hirabayashi, M., M.D., “Early Gastric Cancer and a Concomitant Pregnancy”, The American Surgeon 53:730 (1987).
Huang, J. et al., “Amino/Carboxyl-terminal Deletion Mutants of Human Choriogonadotropin .beta..” The Journal of Biological Chemistry 268:9311 (1993).
Huang, J. et al., “Mutagenesis of the ‘determinant loop’ region of human choriogonadotropin .beta..” Molecular and Cellular Endocrinology 90:211 (1993).
Jain, Scientific American, pp. 58-65, Jul. 1994.
Kumar, S. et al., “Necrosis and Inhibition of Growth of Human Lung Tumor by Anti-.alpha.-Human Chorionic Gonadotropin Antibody.” J. Natl Cancer Inst. 84:42 (1992).
Loosfelt, H. et al., “Cloning and Sequencing of Porcine LH-hCG Receptor cDNA: Variants Lacking Transmembrane Domain.” Science 245:525 (1989).
Mann et al, Scand. J. Clin. Lab. Invest. , Suppl. vol. 216, pp. 97-104, 1993.
Marcillac et al. (1992) Cancer Res. 52: 3901-3907.
McFarland, K.C. et al., “Lutropin-Choriogonadotropin Receptor: An Unusual Member of the G Protein-Coupled Receptor Family.” Science 245:494 (1989).
Nakhai, B. et al., “Over-expression and characterization of recombinant beta subunit of the human chorionic gonadotropin hormone synthesized in insect cells infected with a genetically engineered baculovirus.” Indian Journal of Biochemistry & Biophysics 29:315 (1992).
Northfeldt et al. (1991) Hematology/Oncology Clinics of North America 5: 297-310.
Ozturk, M. et al., “Ectopic .beta.-Human Chorionic Gonadotropin Production by a Human Hepatoma Cell Line (FOCUS): Isolation and Immunochemical Characterization.” Endocrinology 120:559 (1987).
Ozturk, M. et al., “Physiological Studies of Human Chorionic Gonadotropin (hCG), .alpha.hCG, and .beta.hCG as Measured by Specific Monoclonal Immunoradiometric Assays.” Endocrinology 120:549 (1987).
Ross et al., Immunology Today, vol. 11, No. 6, 1990.
Siemen, Rodent Tumor Models in Experimental Cancer Therapy, Edited by Kallman, Pergamon Press, pp. 12-15, 1987.
Sridhar, P. et al., “Differential secretion and glycosylation of recombinant human chorionic gonadotropin (.beta.hCG) synthesized using different promoters in the baculovirus expression vector system.” Gene (Netherlands) 131:261 (1993).
Stenman et al. (1993) Scand. J. Clin. Lab. Invest. Suppl. 216: 42-78.
Strickla

Affiliated with

Also associated with

Rating

Biologically active polypeptides derived from a novel early... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Biologically active polypeptides derived from a novel early..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Biologically active polypeptides derived from a novel early... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2763998